Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial)

INTRODUCTION: Recent preclinical studies have discovered unique synergism between radiotherapy and immune checkpoint inhibitors, which has already brought significant survival benefit in lung cancer. In locally advanced rectal cancer (LARC), neoadjuvant radiotherapy plus immune checkpoint inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Kai, Yang, Yun, Tian, Dan, Zeng, Na, Cao, Shun, Ling, Shen, Gao, Jiale, Zhao, Pengfei, Wang, Hao, Kong, Yuanyuan, Zhang, Jie, Chen, Guangyong, Deng, Wei, Bai, Zhigang, Jin, Lan, Wu, Guoju, Zhu, Danyang, Wang, Yue, Zhou, Jiaolin, Wu, Bin, Lin, Guole, Xiao, Yi, Gao, Zhidong, Ye, Yingjiang, Wang, Xin, Li, Ang, Han, Jiagang, Yao, Hongwei, Yang, Yingchi, Zhang, Zhongtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503326/
https://www.ncbi.nlm.nih.gov/pubmed/37699634
http://dx.doi.org/10.1136/bmjopen-2022-069499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503326/
https://www.ncbi.nlm.nih.gov/pubmed/37699634
http://dx.doi.org/10.1136/bmjopen-2022-069499

Ejemplares similares